Updated January 2021

			1	
	MercyOne Elkader Medical Center, a Health Ministry of Trinity Health, presents the following COVID-19 (Corona Virus) test price information for consumers to consider the cost of testing in our facility(ies).		Please follow the Financial Assistance Policy for MercyOne aligned with 501R guidelines as stated in COVID-19 Self-Pay Price communication document on the Trinity Health COVID Response page here: https://www.mercyone.org/elkader/for-patients/billing-and-financial-information/financial-assistance	
CPT/HCPCS				
Code	CPT Code Description	Consumer friendly description	Standard Price	Cash Price
		COVID-19 Specimen collection, any		
C9803	COVID-19 Specimen collection, any source, nasal, blood, saliva	source, nasal, blood, saliva	N/A	N/A
	Molecular Diagnosticc Testing			
	CDC 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic	CDC COVID-19 VIRUS DETECTION		
U0001	panel	TEST KIT	N/A	N/A
	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any	COVID-19 VIRUS DETECTION TEST		
U0002	technique, multiple types or subtypes (includes all targets), non-cdc	(NON PCR)	\$102	\$66.30
	Infectious agent detection by nucleic acid (DNA or RNA); severe			
	acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	COVID-19 VIRUS DETECTION TEST (BY		
87635	(Coronavirus disease [COVID-19]), amplified probe technique	PCR)	N/A	N/A
	Infectious agent detection by nucleic acid (DNA or RNA); severe			
	acute respiratory syndrome coronavirus 2 (SARS-CoV-2)			
	(Coronavirus disease [COVID-19]) and influenza virus types A and B,	COVID-19, influenza A and B, VIRUS		
87636	multiplex amplified probe technique	DETECTION TEST (BY PCR)	N/A	N/A
	Infectious agent detection by nucleic acid (DNA or RNA); severe			
	acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	COVID-19, influenza A and B,		
	(Coronavirus disease [COVID-19]), influenza virus types A and B,	Respiratory Syncytial VIRUS		
87637	and respiratory syncytial virus, multiplex amplified probe technique	DETECTION TEST (BY PCR)	N/A	N/A
	Infectious agent detection by nucleic acid (DNA or RNA); severe			
	acute respiratory syndrome coronavirus 2 (SARS-CoV-2)			
	(Coronavirus disease [COVID-19]), amplified probe technique,	COVID-19 VIRUS DETECTION TEST (BY		
110003	making use of high throughput technologies as described by CMS-	PCR) High throughput, High Volume	40.0	A4
U0003	2020-01-R	analyzer	\$218	\$141.57
	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any	COMP 10 MINUS DETECTION TEST		
	technique, multiple types or subtypes (includes all targets), non-	COVID-19 VIRUS DETECTION TEST		
U0004	CDC, making use of high throughput technologies as described by CMS-2020-01-R.	(NON PCR) High throughput, High Volume analyzer	\$155	\$100.92
00004	CIVI3-2U2U-U1-N.	volume analyzer	1 3122	\$100.92

	Infectious agent detection by nucleic acid (DNA or RNA); severe			
	acute respiratory syndrome coronavirus 2 (SARS-CoV-2)			
	(Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies,			
	completed within 2 calendar days from date and time of specimen	Use of HIGH Throughput technology		
	collection. (List separately in addition to either HCPCS code U0003	with COVID VIRUS Detection resulted		
U0005	or U0004)	within 48 hours	N/A	N/A
00000	Molecular Testing Panel Codes that include COVID-19	Within 16 Hears	,	.4/.
	Infectious disease (bacterial or viral respiratory tract infection),			
	pathogen specific nucleic acid (DNA or RNA), 22 targets including			
	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),			
	qualitative RT-PCR, nasopharyngeal swab, each pathogen reported	BIOFIRE 2.1 Respiratory Viral Panel		
0202U	as detected or not detected	including COVID-19 (BY PCR)	N/A	N/A
	Infectious disease (bacterial or viral respiratory tract infection),			
	pathogen-specific nucleic acid (DNA or RNA), 22 targets including			
	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),			
	qualitative RT-PCR, nasopharyngeal swab, each pathogen reported	QIAstat-Dx Respiratory SARS-CoV-2		
0223U	as detected or not detected	Panel including COVID-19 (BY PCR)	N/A	N/A
	Infectious disease (bacterial or viral respiratory tract infection)			
	pathogen-specific DNA and RNA, 21 targets, including severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe			
	technique, including multiplex reverse transcription for RNA	ePlex® Respiratory Pathogen Panel 2		_
0225U	targets, each analyte reported as detected or not detected	including COVID-19 (NON PCR)	N/A	N/A
	Infectious disease (viral respiratory tract infection), pathogen-			
	specific RNA, 3 targets (severe acute respiratory syndrome			
	coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper	Cepheid Xpert® Xpress Repiratory		
	respiratory specimen, each pathogen reported as detected or not	Viral Panel including COVID-19,		
0240U	detected	Infuenza A & B (PCR)	N/A	N/A
	Infectious disease (viral respiratory tract infection), pathogen-			
	specific RNA, 4 targets (severe acute respiratory syndrome	Cepheid Xpert® Xpress Repiratory		
	coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory	Viral Panel including COVID-19,		
024411	syncytial virus [RSV]), upper respiratory specimen, each pathogen	Infuenza A & B, Respiratory Syncytial (PCR)	N/A	N/A
0241U	reported as detected or not detected	(PCR)	N/A	N/A
	Antigen Testing Codes			
	Infectious agent antigen detection by immunoassay technique, (eg,			
	enzyme immunoassay [EIA], enzyme-linked immunosorbent assay			
	[ELISA], fluorescence immunoassay [FIA],			
	immunochemiluminometric assay [IMCA]) qualitative or	Canana Vinua (COVID 10 Anti-an		
07426	semiquantitative; severe acute respiratory syndrome coronavirus	Corona Virus/COVID-19 Antigen	Ć4EC	¢101.40
87426	(e.g., SARS-CoV, SARS-CoV-2 [COVID-19])	testing to detect virus	\$156	\$101.40

	Infectious agent antigen detection by immunoassay technique, (eg,			
	enzyme immunoassay [EIA], enzyme-linked immunosorbent assay			
	[ELISA], fluorescence immunoassay [FIA],			
	immunochemiluminometric assay [IMCA]) qualitative or			
	semiquantitative; severe acute respiratory syndrome coronavirus			
	(eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A	Corona Virus/COVID-19, Influenza A		
87428	and B	& B Antigen testing to detect virus	\$286	\$185.84
	Infectious agent antigen detection by immunoassay with direct			
	optical (ie, visual) observation; severe acute respiratory syndrome	COVID-19 Antigen Test By Rapid		
87811	coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	Visual Detection	N/A	N/A
	Antibody Testing Codes			
	Immunoassay for infectious agent antibody(ies), qualitative or			
	semiquantitative, single step method (eg, reagent strip); severe	COVID-19 VIRUS Antibody Detection		
	acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Test, single step (prior Infection of		
86328	(Coronavirus disease [COVID-19])	COVID-19), presence or absence	N/A	N/A
		COVID-19 VIRUS Antibody Detection		
	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-	Test, complex (prior Infection of		
86769	CoV-2) (Coronavirus disease [COVID-19])	COVID-19), presence or absence	N/A	N/A
		COVID-19 VIRUS Antibody		
	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Quantitiative Test, (prior Infection of		
86413	(Coronavirus disease [COVID-19]) antibody, quantitative	COVID-19)	N/A	N/A
		COVID-19 VIRUS Blocking Antibody		
	Neutralizing antibody, severe acute respiratory syndrome	Test, (immunoresponse to block		
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]);	future infections of COVID-19),		
86408	screen	Presence or absence	N/A	N/A
		COVID-19 VIRUS Blocking Antibody		
		Quantitative Test, (immunoresponse		
	Neutralizing antibody, severe acute respiratory syndrome	to block future infections of COVID-		_
86409	coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]);titer	19)	N/A	N/A
	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-			
	CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when	COVID-19 Antibody Test, performed		_
0224U	performed	by Mount Sinai Laboratory	N/A	N/A
		COVID-19 VIRUS Blocking Antibody		
		Test, (immunoresponse to block		
		future infections of COVID-19),		
	Surrogate viral neutralization test (sVNT), severe acute respiratory	Presence or absence, Tru-		
022611	syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease	ImmuneTM, Ethos Laboratories,	21/2	
0226U	[COVID-19]), ELISA, plasma, serum	GenScript® USA Inc	N/A	N/A